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HIGHLIGHTS
 Antiarrhythmic therapies remain suboptimal due to our inability to predict how drug interactions with ion
channels will affect the ability of the tissue to initiate and sustain an arrhythmia.
 We built a computational framework that allows for in silico design of precision-targeted therapeutic agents
that simultaneously assesses antiarrhythmic markers of success and failure at multiple spatial and time scales.
Using this framework, a novel in silico mexiletine “booster” was designed that may dramatically improve the
efﬁcacy of mexiletine in suppression of arrhythmia triggers.
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A New Molecular Target for Antiarrhythmic Drugs

 These results provide a roadmap for the design of novel molecular-based therapy to treat myriad arrhythmia
syndromes, including ventricular tachycardia, heart failure arrhythmias, and inherited arrhythmia syndromes.
 In summary, computational modeling approaches to drug discovery represent a novel tool to design and test
precision-targeted therapeutic agents. By exploiting nontraditional ion channel drug targets, an entirely new
dimension can be added to the wide parameter space of traditional antiarrhythmic drugs to develop more
precision-targeted and potent Class I therapeutic agents.

ABBREVIATIONS
AND ACRONYMS
APD = action potential
duration

BCL2000 = basic cycle length
of 2,000 ms

DIII-VSD = domain III voltagesensing domain

SUMMARY

EAD = early
afterdepolarization

Antiarrhythmic treatment strategies remain suboptimal due to our inability to predict how drug interactions
with ion channels will affect the ability of the tissues to initiate and sustain an arrhythmia. We built a multiscale
þ

molecular model of the Na channel domain III (domain III voltage-sensing domain) to highlight the molecular
underpinnings responsible for mexiletine drug efﬁcacy. This model predicts that a hyperpolarizing shift in the
domain III voltage-sensing domain is critical for drug efﬁcacy and may be leveraged to design more potent
Class I molecules. The model was therefore used to design, in silico, a theoretical mexiletine booster that can
dramatically rescue a mutant resistant to the potent antiarrhythmic effects of mexiletine. Our framework
provides a strategy for in silico design of precision-targeted therapeutic agents that simultaneously assesses
antiarrhythmic markers of success and failure at multiple spatial and time scales. This approach provides a
roadmap for the design of novel molecular-based therapy to treat myriad arrhythmia syndromes,

IC50 = half-maximal inhibitory
voltage

LQT3 = long QT syndrome
type 3

RFI = recovery from
inactivation

SSA = steady-state availability
UDB = use-dependent block
V1/2 = half-maximal voltage
VSD = voltage-sensing domain

including ventricular tachycardia, heart failure arrhythmias, and inherited arrhythmia syndromes.
(J Am Coll Cardiol Basic Trans Science 2019;4:736–51) © 2019 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).

C

urrent antiarrhythmic treatment strategies

trial-and-error approach to choosing appropriate

remain suboptimal due to our inability to

pharmacotherapy for patients. Furthermore, despite

predict patient-speciﬁc responses. As evi-

an enormous amount of research into antiarrhythmic

denced by large clinical trials (e.g., CAST [Cardiac

drug therapy that has produced molecules with a

Arrhythmia Suppression Trial] [1], SWORD [Survival

wide range of pharmacokinetic properties, they all

With Oral d-Sotalol] [2]), antiarrhythmic therapy can

block a single target: the channel pore. Thus, targets

paradoxically increase arrhythmia burden compared

of ion channels other than the channel pore may

with placebo and lead to increased risk of death.

add an entirely new dimension to antiarrhythmic

This outcome is due, in part, to the complex kinetics

drug therapy.

of the drug channel interaction that includes strong

SEE PAGE 752

bidirectional feedback between how drugs alter the
voltage-

Structurally, the alpha-subunit of Naþ channels is

dependent potency, as well as electrotonic coupling

formed by a monomer with 4 homologous domains

in tissue, which we (3) and others (4) have shown

(DI to DIV), each with 6 transmembrane subunits (S1

can lead to an even more complex response to

to S6). The S1-S4 of each domain forms the voltage-

drugs that may not be appreciated in single-cell

sensing domain (VSD), and S5-S6 forms the pore

studies. For both acquired and inherited arrhythmia

(5,6). Upon membrane depolarization, the VSDs acti-

syndromes, this scenario leads to a dangerous

vate and open the pore, allowing Na þ entry into the

action

potential

waveform

affecting
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cell. Experimental recordings that monitor VSD

agents and allow for a lower concentration of drugs to

conformation changes (voltage clamp ﬂuorometry)

be used, decreasing off-target side effects.

have shown that VSD movement is modulated by
binding of local anesthetics, and that when lidocaine

METHODS

binds to the Naþ channel, it stabilizes the domain III
VSD (DIII-VSD) in an activated conformation (7). Our

Computational Markov models of the WT, M1652R,

recent experimental results (8) show that DIII-VSD

and R1626P LQT3 mutants were formulated with and

dynamics signiﬁcantly regulate mexiletine blockade

without the mexiletine drug channel interaction via

of NaV1.5, and the differential response of long QT

numerical optimization from experimental data, as

syndrome type 3 (LQT3) carriers to mexiletine is due,

previously described (12,13). These models include
both channel kinetics and voltage-clamp ﬂuorescence

in large part, to mutation-speciﬁc VSD dynamics.
To date, the myriad parameters within Na þ channel

describing the DIII-VSD movement. The drug channel

kinetic models have been shown to have a signiﬁcant

model was incorporated into a computational model

impact on the ability of the heart to initiate and sus-

of the human ventricular myocyte (14) to assess

tain an arrhythmia, and exploiting these parameters

cellular and tissue response to drug therapy. Our

has been useful for understanding Na þ channel

model incorporates experimental data from HEK cells

pharmacology (9). However, it has not yet been

and from the Xenopus cell expression system where

possible to design targeted interventions that alter

appropriate.

these parameters because they are not speciﬁcally

Results for experimental data are expressed as
mean  SEM. Signiﬁcance between groups was tested

connected to the channel structure.
The current study used our experimental results

by using the Student’s t-test. We have used a variety

(8) to develop a computational model that tracks

of ﬁgure types to best display the experimental data.

molecular DIII-VSD movement, Na þ channel electro-

The model-ﬁtting plots are scatter plots of the sum-

physiology, and the response of both to mexiletine

mary experimental data (points, experiment) with the

drug blockade for 2 LQT3 mutations: R1626P, shown

simulated model ﬁts shown as linear overlays. The

to be mexiletine sensitive, and M1652R, shown to be

tissue data are displays of cellular action potential as

mexiletine resistant. The ﬁdelity of the model for

well as simulated individual currents (e.g., Naþ cur-

these 2 mutants provides conﬁdence that the relation

rent). Summary data for the biotin experiments are

between the DIII-VSD and channel gating is well

shown as bar plots. Detailed methods are available in

represented by the model and allows us to predict

the Supplemental Information.

novel therapeutic approaches based on this relation.
This ﬁnding is clinically important; despite the com-

RESULTS

mon use of mexiletine in treating ischemia-related
ventricular tachycardia in those without Na þ chan-

BIOPHYSICAL CHARACTERISTICS OF 2 LQT3 MUTANTS.

nel mutations (WT), its effectiveness is suboptimal,

We focused on the R1626P (RP) and the M1652R (MR)

necessitating high clinical doses, and plagued by

mutations because of their marked differential re-

numerous side effects. Our previous study conﬁrms

sponses to mexiletine. Both mutations lie within the

this lack of efﬁcacy in WT channels.

DIV S4 segment and produce an increased late Naþ

To our knowledge, this is the ﬁrst such multiscale

current w0.7% to 1.0% of the peak current. Aside

computational model that explicitly displays the

from a w15 mV depolarizing shift in steady-state

experimentally

un-

availability (SSA) for the MR mutation, and a w8 mV

derpinnings of drug efﬁcacy from channel kinetics to

hyperpolarization of the RP mutation, the electro-

higher dimensional cardiac ﬁbers (10,11). Using the

physiology of both mutations is similar (15). At resting

model as a therapeutic prediction tool, we then

membrane potential, however, the DIII-VSD of RP is

parameterized

molecular

developed an in silico mexiletine “booster”: a theo-

nearly w90% activated (“up” position), whereas the

retical drug that alters DIII-VSD activation kinetics

MR DIII-VSD is only w50% activated (8).

and signiﬁcantly enhances drug efﬁcacy. We propose
pore

DRUG-FREE MODEL DEVELOPMENT. We began by

blockers, enhanced by allosteric channel modulation,

developing drug-free models of both mutations as

could dramatically alter the landscape for antiar-

well as wild type, which were easily ﬁt with a well-

rhythmic therapy by adding another dimension to the

established 8-state Markov model (3). The late cur-

parameter space of drug efﬁcacy. This approach

rents of the mutations were simulated as slowly

would expand the number of patients who would

inactivating currents and were numerically optimized

receive clinical beneﬁt from existing therapeutic

to yield 0.1%, 0.67%, and 1% late current (ratio to the

that

combination

therapy

with

common
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F I G U R E 1 Model Schematic With Drug-Free Kinetics

(A) Topology of the NaV1.5 channel and location of the 2 long QT mutations with distinct mexiletine sensitivity, R1626P (red ball, sensitive) and M1652R (green ball,
insensitive). A ﬂuorophore is attached to domain III (DIII). (B) Schematic representation of the DIII voltage-sensing domain (DIII-VSD) in the Naþ channel and corresponding Markov state-chain diagram of the drug-free Naþ channel. The blue DIII-VSD is in a “down” or rested position and corresponds to the blue “R” states in the
Markov model (far right). The green DIII-VSD represents the ﬁrst transition to a ﬂuorescent regime labeled “A1” (ﬁrst activated) and corresponds to the green “A1”
states in the Markov model. The second transition to A2 is denoted with the red DIII-VSD, which represents a “fully up” state and corresponds to the “A2” states. As
depicted, the model includes 16 states: 4 rested states (“R”), 4 ﬁrst-activated states (“A1”), and 8 second-activated states (“A2”). The rate constants governing the
transitions can be found in the Supplemental Material. (C) Current kinetics. In each panel, the points represent the experimental data, and the solid lines represent the
model ﬁts to the data. WT is shown in black, M1652R is shown in red, and R1626P is shown in blue. The triangles in the steady-state availability (SSA) plot indicate the
HEK transformation of the SSA, detailed in the Supplemental Material. The model ﬁts to current kinetics include steady-state availability, activation, recovery from
inactivation, Tau of deactivation (not shown), and mean open time (for WT). Details of the protocols are given in the Supplemental Material. (D) Representative traces
of currents in the 3 constructs. Shown at left is the experiment, right is the simulation. The channel was held at –120 mV to steady state and then pulsed to 0 mV for
25 ms. WT is in black, M1652R is in red, and R1626P is in blue. (E) Fluorescent kinetics. In each panel, the points represent the experimental data, and the solid lines
represent the model ﬁts to the data. WT is shown in black, M1652R is shown in red, and R1626P is shown in blue. Shown are ﬂuorescent activation and deactivation.
(F) Representative traces of ﬂuorescence in the 3 constructs (WT, black; M1652R, red; R1626P, blue). Shown at left is the experiment, right is the simulation for 4
different test voltages (–160 mV, –100 mV, –40 mV, and 0 mV; the voltage protocol is shown in the inset). The experimental data for steady-state activation and
recovery from inactivation are from Ruan et al. (15); the experimental data for SSA, ﬂuorescent activation, and ﬂuorescent tau are from Zhu et al. (8).
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F I G U R E 2 Mexiletine Drug-Binding Kinetics

In each panel, the points represent the experimental data, and the solid lines represent the model ﬁts to the data. WT is shown in black, M1652R is shown in red, and
R1626P is shown in blue. (A) SSA with mexiletine 250 mM. As in Figure 1, the triangles represent the HEK transformation (Supplemental Material). There is a minimal
shift in SSA with mexiletine, indicating minimal inactivated state binding. (B) Use-dependent block with mexiletine 0.1 to 1,000 mM. There is a 10 times differential
sensitivity to mexiletine between MR (blue) and RP (red). (C) Tonic block with mexiletine 0.1 to 1,000 mM. The marked differential sensitivity persists for tonic block,
similar to the use-dependent block seen in panel B. (D) Recovery from inactivation at –100 mV with mexiletine 250 mM. (E) Fluorescent activation with 4,000 mM
mexiletine. Note the marked hyperpolarization of all 3 constructs with mexiletine, indicating that mexiletine stabilizes DIII-VSD in the activated conformation. (F) Late
block with mexiletine 75 mM. Similar to the experiment, there is increasing afﬁnity of late current block (measured after 400 ms of a depolarizing pulse) between the
3 constructs: WT < M1652R < R1626P. Details of the protocols can be found in the Supplemental Material. Abbreviations as in Figure 1.

peak current) for the WT, M1652R, and R1626P con-

data showing multiple time constants in response to

structs, respectively (15). We then focused on

depolarizing pulses of different durations suggest at

expanding the kinetic model to account for DIII-VSD

least 2 active conformations of the DIII-VSD (16,18).

movement, shown to be stabilized in an active

Therefore, to best ﬁt the ﬂuorescent data, 3 regimes

conformation by mexiletine (8). Using voltage-clamp

were added to the model: a row of resting closed

ﬂuorometry methods previously described (16), the

states (RC1 – RC4) which represent DIII-VSD in a

kinetics of DIII-VSD were simulated in response to

“down” position; a ﬁrst-activated regime (A1C3 –

channel activation. Brieﬂy, by attaching a ﬂuorescent

A1C4), which represents the ﬁrst activation of the

tag to the DIII-VSD and expressing NaV 1.5 in a Xen-

DIII-VSD (DIII “moving up”); and a second-activated

opus oocyte cell expression system, we could simul-

regime (A2 states) which represents the second-

taneously record current kinetics and DIII-VSD

activation step of DIII-VSD (DIII “fully up”) and

movement (16,17).

contains the top 8 states. The full 16-state drug-free

As can be seen in Figure 1E, much of the DIII-VSD

model is shown in Figure 1B. Fluorescence was then

movement occurs in a voltage range before Na þ

simulated by plotting the ratio of the sum of the A1

channels begin to activate. At –80 mV, the RP DIII-

and A2 states to the total states. As detailed in the

VSD is w90% in the active position, whereas the

Supplemental Material, analysis of the half-maximal

MR DIII-VSD is only w50% activated. Experimental

voltage (V 1/2) of DIII-VSD activation versus tonic
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block with mexiletine allowed us to tease out the

seen for 15 different mutants were primarily accoun-

relative ﬂuorescent contributions of the A1 and A2

ted for by the difference in the DIII-VSD. For the RP

states (Supplemental Figure 7).

mutation, the V 1/2 of DIII-VSD activation is –143 mV

One beneﬁt of using a computational approach is

and has a 10-fold lower half-maximal inhibitory con-

that data from different expression systems can be

centration (IC50 ) for tonic block (69.5 mM), compared

reconciled by altering the appropriate parameters.

with MR, which has a V 1/2 of –100 mV and a tonic

For example, in simulating MR SSA, we chose to

block IC 50 of 624 mM. Our results, as well as others

incorporate a 15 mV depolarizing shift of MR

(15), suggest that the intrinsic afﬁnity of mexiletine to

compared with WT to more closely simulate the re-

the local anesthetic receptor for the mutants is likely

sults obtained by us and others (15) in the HEK

the same, but the measured tonic block differences

expression system. Thus, in Figure 1C (SSA), the red

represent both contamination by the inactivated state

circles represent data obtained in Xenopus oocytes,

and differences in DIII-VSD guarding the receptor.

the red triangles represent the “HEK-transformed”

Taken together, we simulated mexiletine drug block

SSA curve (þ15 mV depolarization), and the solid red

as transitions only from the A2 states to the drug-

line represents the model ﬁt. Overall, Figure 1 shows

bound states; in other words, DIII-VSD needs to be

that the resultant simulations (solid lines) match

in a fully activated (A2 regime) position to allow for

closely with the experimental data (points) and cap-

drug binding.

ture a wide range of channel kinetics.
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The resultant models after numerical optimization

Figures 1D and 1F present a side-by-side comparison

(Supplemental Material) are shown in Figure 2, with

of the simulated Naþ channel currents and ﬂuores-

additional biophysical characterization shown in

cence traces in response to a voltage step protocol. As

Supplemental Figure 2. As can be seen, the model

can be seen, for both mutations and WT, the activa-

simulations ﬁt the experimental data over a wide

tion of DIII-VSD to depolarized potentials is rapid and

range of pacing protocols and drug concentrations.

on the order of 3 to 5 ms, similar to current activation.

Similar to the experimental data, there are marked

At a membrane potential of –120 mV, WT is w50%

differences in the afﬁnities of mexiletine between the

activated (“up”), MR is w25% activated (“up”), and

2 mutants for both use-dependent block (UDB) and

RP is w75% activated (“up”). In general, over the

tonic block, with the RP mutation exhibiting a 10 to 15

physiological voltage range, the RP mutation traps

times increased sensitivity to mexiletine compared

the DIII-VSD in a relatively activated position, a

with MR (tonic block: 69.5 m M vs. 625 m M; UDB: 16 m M

necessary prerequisite for drug binding (discussed in

vs. 240 m M). In the model, these differences are

the following section).

largely regulated by the difference in DIII-VSD acti-

Experimentally, maximal ﬂuorescence occurs at

vation (Figure 2E), given that the intrinsic afﬁnity of

the most hyperpolarized potentials, which implies

mexiletine to the receptor for the 3 models was

that the ﬂuorescent molecule, TAMRA-MTS, is being

optimized to a constant afﬁnity (156 m M). Recovery

quenched at elevated membrane voltages. Thus, DIII-

kinetics with mexiletine are similar between the 2

VSD activation is inversely proportional to ﬂuores-

mutants (Figure 2D), which are both faster than WT.

cence, and the plots are normalized to the range of

Application of mexiletine 4,000 m M stabilizes the

minimal to maximal ﬂuorescence. As such, Figure 1E

DIII-VSD in the activated position (shifts the DIII-VSD

is labeled as “DIII-VSD activation” (which is equiva-

to more hyperpolarized potentials) by 13 mV for RP

lent to the DIII-VSD position in the membrane). This

(–156.8 mV vs. –143 mV) and by 22 mV for MR

is congruent with Figure 1F labeling: at –160 mV, all

(–122.2 mV vs. –100 mV). Mexiletine application also

constructs ﬂuoresce maximally, shown as the upward

slows recovery of DIII-VSD ﬂuorescence (Tau Recovery :

deﬂection of the ﬂuorescence curve. Upon depolari-

RP 19.05 ms [experiment] vs. 19.02 ms [simulation];

zation, the ﬂuorescence is quenched to 0%, as DIII-

MR 14.2 ms [experiment] vs. 14.2 ms [simulation after

VSD is in an “up” position.

a depolarizing pulse to 20 mV). Late current block, the

MEXILETINE DRUG-BOUND MODEL DEVELOPMENT.

amount of current blocked by mexiletine 75 m M after a

We next expanded the model to account for mex-

400 ms depolarizing pulse, is shown in Figure 2F. The

iletine drug binding. Our previous results suggested

RP mutation is slightly more sensitive to late current

that the voltage dependence of DIII-VSD activation

block than MR (50% vs. 35% block).

strongly correlates with tonic block by mexiletine

CELLULAR SIMULATIONS RECAPITULATE DIFFERENTIAL

(Figure 4 of Zhu et al. [8]). Brieﬂy, tonic block, a

SENSITIVITIES TO MEXILETINE. The

measure of ﬁrst-pulse block, is assessed at holding

to incorporate our Naþ channel models into the

potentials before much closed-state inactivation oc-

Grandi-Bers computational model of the human

curs; thus, the apparent differences in tonic block

ventricular myocyte (14), with substitution of our Na þ

next step was
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F I G U R E 3 Cellular Level Effects of Mex at Bradycardic Pacing

Continued on the next page
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channel model for the baseline formulation and

mexiletine booster and then tested its efﬁcacy in

modiﬁcation of the maximum chloride conductance

combination with mexiletine.

of the baseline model for more accurate repolariza-

This concept was ﬁrst tested experimentally

tion (Supplemental Material). We focused on a slow-

(Figure 4). We used MTSEA-biotin (biotin) to alter the

pacing regime of 0.5 Hz (basic cycle length of

conformation of the DIII-VSD. It was previously

2,000 ms [BCL2000]) for our cellular simulations. In

shown that extracellular application of biotin can

the drug-free conditions, both MR and RP display

modulate the cysteine residue at the 1,306 location

marked prolongation in action potential duration at

(7,19). It stabilizes the DIII-VSD in an activated posi-

90% repolarization (APD90 ), as well as sustained late

tion in R1306C channels. We engineered the R1306C

Naþ current (Figures 3B and 3C). Interestingly, the MR

mutation as a biotin target, as well as an R1306C

mutation displays chaotic behavior, including pro-

M1652R double mutation into NaV 1.5, and expressed

gressive APD prolongation until the onset of early

the mutant channels in the HEK cell expression sys-

afterdepolarizations (EADs), a hallmark bradycardic

tem. As shown in these previous studies, application

arrhythmia trigger, as well as salvos of sustained de-

of biotin to R1306C channel decreases peak Naþ cur-

polarization (Figure 3B, Supplemental Figure 4).

rent, which stabilized w20 min after biotin perfusion.

Application of mexiletine 10 m M (high clinical con-

The decrease in Naþ current amplitude suggests that

centration) is unable to normalize APD 90 : w509 ms

MTSEA-biotin binds to the cysteine residue and

versus w523 ms in the drug-free condition. In

modulates the DIII-VSD conformation. We also

contrast, the RP mutation shows stable EADs, with an

observed a reduction in peak Naþ current in the

APD 90 of w1,047 ms in the absence of drug. Applica-

double-mutant R1306C M1652R 20 min after biotin

tion of mexiletine 10 m M is able to decrease the APD 90

application (Figure 4B). Biotin caused a small depo-

of RP by 28% and abolish the EAD triggers, similar to

larizing shift in the activation (conductance-voltage

clinical results (Figure 2 in Ruan et al. [15]). As ex-

[GV]) curve, but no effect on the SSA curve, for the

pected, mexiletine had negligible effects on WT

R1306C channel (Figure 4C). Similar to the M1652R

APD 90 . Consistent with other Class Ib antiarrhythmic

channel, the double-mutant R1306C M1652R channel

drugs, mexiletine 10 m M has negligible effects on

exhibited a large depolarizing shift in the SSA

maximum upstroke velocity (Supplemental Figure 3).

curve compared with the R1306C channel (R1306C

“BOOSTER”.

V1/2 ¼ –79.5  1.2 mV; R1306C M1652R V1/2 ¼ –59.0 

Given mexiletine’s safety and widespread use in the

2.7 mV) (Figures 4C and 4D). This depolarizing shift

clinic, we hypothesized that combination therapy

increases the availability of the channel (gain of

with mexiletine and a “booster” drug might synergize

function). Notably, when the R1306C M1652R channel

for more potent antiarrhythmic effects. Because

was modiﬁed with a biotin, the SSA curve was shifted

mexiletine sensitivity between RP and MR seems to

to hyperpolarizing potentials (V 1/2 ¼ –66.1  3.8 mV).

be driven by the relative position of the DIII-VSD, we

Thus, biotin partially corrects the alteration of the

hypothesized that by holding the DIII-VSD in an “up”

SSA curve caused by the M1652R mutation.

DEVELOPMENT

OF
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A

MEXILETINE

and activated position, we could enhance the efﬁcacy

Finally, we tested block by mexiletine 50 m M in

of mexiletine for patients found to be mexiletine

R1306C and R1306C M1652R channels modiﬁed by

resistant (e.g., MR mutants). We thus turned to the

biotin. There was a signiﬁcant 81% and 146% increase

computational model to design (i.e., in silico) a

in tonic block in the R1306C and R1306C M1652R

F I G U R E 3 Continued

(A) Schematic of single-cell simulations. The Markov model representation of the Naþ channel was placed into an action potential (AP) model,
replacing the standard Hodgkin-Huxley formulation. (B) Single-cell APs at basic cycle length 2,000 ms (BCL2000) for M1652R. In the
absence of mexiletine (Mex), the M1652R mutation displays chaotic behavior with failure to repolarize (black trace). Application of Mex 10 mM
(red trace) induced single early afterdepolarizations (EADs) but enhanced repolarization. Wild type, drug free is shown in gray. (C) Naþ
currents for the corresponding APs shown in panel B. Note that the drug-free condition induces sustained inward current (black trace).
Despite high clinical Mex (10 mM), Naþ channels reactivate, which causes the EADs shown in B. (D) Single-cell APs at BCL2000 for R1626P. In
the absence of Mex, the R1626P shows characteristic EADs and a markedly prolonged AP duration (APD, black trace). Application of Mex
10 mM (red) successfully abolished the EADs, leading to monotonic repolarization but still with a prolonged APD compared with wild type
(gray trace). (E) Naþ currents for the corresponding APs shown in D. Note the shortened late inward Naþ current with application of Mex.
(F) APD as a function of cycle number for 100 beats at BCL2000 (corresponding to the APs shown in B and D). Note in the M1652R panel, the
blue arrow at beat 42 corresponds to the blue arrow in B depicting the onset of a failure of the repolarization regime. For the R1626P
mutation, the red arrow corresponds to beat 40, shown in D. Note the beat-to-beat APD variability with Mex 5 mM (blue trace). After early
chaos (ﬁrst 10 beats), Mex 10 mM induces monotonic repolarization (absence of EADs), shown as the red curve in F (far right).
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F I G U R E 4 Effects of Biotin on the DIII-VSD and Optimization of a Mex “Booster”

(A) Schematic of the Naþ channel with the double-mutation R1306C M1652R. Application of MTSEA-biotin traps the DIII-VSD (pink) in the activated position. (B)
Representative current traces of the R1306C and R1306C M1652R channels before and 20 min after MTSEA-biotin 20 mM perfusion. Peak current amplitude for both
constructs decreased after MTSEA-biotin application. (C) Effects of biotin on channel activation (conductance-voltage [GV]) and SSA of the R1306C channel. Application
of biotin induces a small right shift in the GV curve. Results are expressed as mean  SEM from a group of 4 to 6 cells. (D) Effect of biotin on GV and SSA of the
M1652R R1306C double mutant. Biotin induces a hyperpolarizing shift in SSA, compared with control. (E) Summary data of tonic block. Application of MTSEA-biotin
to both mutants induces a signiﬁcant w2 times increase in tonic block for Mex 50 mM. Signiﬁcance was determined by using the Student’s t-test. **p < 0.01,
***p < 0.005. (F) Use-dependent block (UDB) for Mex 50 mM. UDB is measured by applying eight 400 ms depolarizing pulses at a 2 Hz frequency to mimic a
tachycardia condition. Although there was a trend of decreasing availability after biotin for both constructs, the changes were not signiﬁcant. (G) Optimization of a
Mex booster. Starting with the optimized parameters from the M1652R mutation (baseline Mex model shown in the black dashed curve), the parameters for DIII-VSD
movement were optimized to induce a 15 mV hyperpolarization in SSA and a 2-fold increase in tonic block and UDB. After optimization, the Mex booster is shown in
blue. As in D, the “booster” rescues SSA back to WT. UDB (top middle) and tonic block (top right) exhibit marked increased afﬁnity with the Mex booster (blue trace)
compared with the baseline Mex model (black dashed traces). Recovery from inactivation (bottom left), ﬂuorescent activation (bottom middle), and late block
(bottom right) with Mex 75 mM are plotted in the same fashion, but these 3 protocols were not used for optimization. They serve as model predictions (details are
given in the text). Abbreviations as in Figures 1 and 3.
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channels, respectively (Figure 4E). In addition, for the

allows increased mexiletine access. In Figure 5B, the

double mutant, mexiletine 50 m M blocks 17.4  6.1%

action potentials Na þ current and APD 90 are plotted

late current; the addition of biotin and mexiletine

in response to boosted mexiletine in a fashion

50 m M blocks 65.3  5.6% late current (p ¼ 0.004). It is

similar to that shown in Figure 3. Combination

noteworthy that the late current was quantiﬁed 50 ms

therapy dramatically shortened APD and late Na þ

after a depolarization pulse of –40 mV. For mexiletine

current and rescued the phenotype to resemble WT.

UDB, there was no signiﬁcant difference between

This boost is further shown with the monotonic,

channels with or without biotin (Figure 4F). This

stable APDs as a function of cycle in Figure 5B. In

result is possibly due to MTSEA-biotin immobilization

sum, a mexiletine booster that was designed to hold

of the DIII-VSD in the activated conformation, which

up DIII-VSD in drug-free conditions enhances mex-

eliminates dynamic control of channel gating by the

iletine efﬁcacy and normalizes cellular markers of

DIII-VSD. Overall, these experiments are congruent

arrhythmia.

with our hypothesis that “pulling up” the DIII-VSD

To further characterize the efﬁcacy of the mex-

with a small molecule has the potential to enhance

iletine booster, an in silico dose-ﬁnding experiment

mexiletine efﬁcacy.
To design an in silico booster, we modiﬁed the
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was conducted in which we quantiﬁed the “equivalent dose” of mexiletine that would be needed to

rates of the DIII-VSD movement in the drug-free

achieve

model of MR (i.e., ax, bx, ay, by, a3, b3), while

booster þ mexiletine 10 mM; the experiment used

comparable

results

with

the

combined

keeping the drug-bound rates constant, to simulate a

simulations in increments of 5 mM mexiletine, start-

15 mV hyperpolarizing shift of SSA (in the absence of

ing from the maximum therapeutic dose (10 m M). As

mexiletine) and a 2-fold increase in tonic block and

can be seen in Figure 6, achieving similar APD short-

UDB in the presence of mexiletine. The results of

ening at BCL2000 with combination therapy (com-

simulated biotin are shown in Figure 4G. As can be

bined booster þ mexiletine 10 mM) would require

seen, in silico biotin shifts the SSA back to WT and

mexiletine 40 mM monotherapy, a 400% increase over

signiﬁcantly increases both tonic block (IC50 105 mM

the therapeutic limit used clinically. Thus, the use of

vs. 400 m M) and UDB (IC50 125 m M vs. 200 mM). We

a

simulated the effects of recovery from inactivation

without a concomitant increase in potentially adverse

(RFI), DIII ﬂuorescence, and late block as conﬁrma-

supratherapeutic dosages of mexiletine.

mexiletine

booster

allows

increased

efﬁcacy

tory validation (e.g., these protocols were not
used in the optimization routine). Thus, our model

1-DIMENSIONAL

predicts that when DIII-VSD is held up, which

THE ANTIARRHYTHMIC EFFICACY OF A MEXILETINE

shifts SSA, recovery from inactivation is slowed.

BOOSTER

Furthermore, even at signiﬁcantly hyperpolarized

BLOCK. We then simulated the effects of mexiletine

potentials, DIII-VSD remains in the up and activated

alone

position. Interestingly, we found no appreciable

1-dimensional cardiac ﬁber. As with the single-cell

increased late current blockade (as a percentage of

results,

peak current block), although an examination at the

throughout a 1-dimensional simulation of a 100-cell

and

TISSUE

WITHOUT

boosted

there

was

SIMULATIONS
INDUCING

mexiletine
sustained

CONFIRM

CONDUCTION

in

APD

a

100-cell

lengthening

actual Na þ current trace (Figure 4G) exhibited mark-

cardiac ﬁber for both RP and MR. The 49th and 50th

edly less late current compared with drug-free

beats of a simulation at a BCL2000 were plotted. For

conditions.

the MR mutation, these beats are in the sustained

When application of boosted mexiletine was

depolarization regime. Application of mexiletine

simulated in single cells, a dramatic response in the

10 m M (Figures 7B and 7C) shortened the APD for each

M1652R mutation was observed. Figure 5A shows the

mutant, but EADs persisted for the MR mutation. In

movement of the DIII-VSD during the action poten-

contrast, boosted mexiletine (Figure 7D) proves efﬁ-

tial for the 3 constructs. For WT, the DIII-VSD tran-

cacious in rescuing the MR mutation back to the

sits between 92% and 100% “up” during an action

WT phenotype.

potential. For RP, the DIII-VSD remains nearly 100%

Lastly, we assessed for conduction block by

up throughout the entire duration of the action po-

measuring

tential, underlying the sensitivity of RP to mex-

1-dimensional ﬁber using the same simulation con-

iletine. In contrast, the DIII-VSD of MR, even with

ditions as in Figure 7 (100 cells, BCL2000, 50 beats).

mexiletine 10 mM, transits between 75% and 100%

Within the therapeutic range of drug concentrations

activated, with most of the cardiac cycle at 75%

and pacing conditions seen clinically, mexiletine

(during diastole). Application of boosted mexiletine

exhibited a strong degree of safety. The full analysis

holds “up” the DIII-VSD to w90% (similar to WT) and

can be found in the Supplemental Material.

conduction

velocity

throughout

a
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F I G U R E 5 Effects of “Boosted” Mex Cellular Dynamics

(A) Overlay of APs and DIII-VSD ﬂuorescence in the absence (black) and presence (red) of Mex 10 mM for WT (left), R1626P (middle), and M1652R (right). In response
to voltage depolarization (the AP), the DIII-VSD (dashed lines) ﬂuoresces before decaying to its resting value at –80 mV (w93% for WT). For R1626P, the DIII-VSD
remains 100% activated throughout the duration of the AP. In M1652 (far right), the DIII-VSD relaxes to w75%, activated both in the presence and absence of Mex.
Application of “boosted” Mex “holds up” the DIII-VSD to w90% (dashed blue trace). (B) The effects of “boosted” Mex (Mex 10 mM þ “booster”) on APs. “Boosted”
Mex (shown in blue) abolishes EAD triggers, failed repolarization, and normalizes the AP toward WT (gray trace). (C) Late Naþ current is dramatically decreased, with
a monotonic decrease back to baseline after each AP, similar to WT. (D) APD as a function of cycle number for 100 beats at BCL2000 corresponding to the APs shown
in B. Note that with “boosted Mex” (blue dots), there is normalization of APD similar to WT. Abbreviations as in Figures 1 and 3.

DISCUSSION

intercalated disc. However, given the current limitations and pressing need for novel therapeutic agents,

Despite numerous clinical failures (2,20), antiar-

we asked the question, can we use modulators of the

rhythmic drug therapy remains a cornerstone for the

channel other than the pore as novel drug targets to

pharmacological

increase the dimensionality of the classic antiar-

management

of

ventricular

arrhythmia. To date, all antiarrhythmic drugs are

rhythmic drugs?

variations on a similar theme: blockade of the channel

To create our model, 2 unique LQT3 mutations

pore with varying pharmacokinetic parameters lead-

were used as “guideposts,” given their varied clinical

ing to varied and often unpredictable efﬁcacy. Greer-

responses to mexiletine (8,15,22). These data allowed

Short et al. (21) recently reported suppression of late

us to integrate our experimental ﬁndings into a model

current in LQT3-associated mutants by narrowing

of the Na þ channel that is able to explicitly represent

intracellular cleft separation, a mechanism that de-

the molecular movements shown to be critical for

pends on the local clustering of Na þ channels at the

mexiletine drug efﬁcacy. To our knowledge, this

Downloaded for Anonymous User (n/a) at Washington University in Saint Louis Bernard Becker Medical Library from ClinicalKey.com by Elsevier on November 12, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.

Moreno et al.

JACC: BASIC TO TRANSLATIONAL SCIENCE VOL. 4, NO. 6, 2019
OCTOBER 2019:736–51

747

A New Molecular Target for Antiarrhythmic Drugs

F I G U R E 6 Dose-Finding Strategy for Equivalence Between Mex and Mex þ Booster

(A) Shown are APs at BCL2000, equivalent to Figure 5, at the juncture where the M1652R mutation starts the failure of the repolarization
regime. After dose ﬁnding, Mex 40 mM gives APD shortening similar to that of Mex 10 mM þ booster. (B) APD over the course of 100 cycles
at BCL2000. The addition of Mex 10 mM (red trace), induces repolarization at every beat, but EADs persist. This was abolished with Mex
10 mM þ booster (blue). To achieve equivalent APD shortening with Mex monotherapy would require Mex 40 mM (gray), a 4-fold increase
from the upper therapeutic range of Mex used clinically. APD90 ¼ action potential duration at 90% repolarization; other abbreviations as in
Figures 1 and 3.

analysis is the ﬁrst such computational model to

We

began

by

using

2

LQT3

mutations

to

represent targetable molecular movements respon-

parameterize our kinetic model: R1626P, a mexiletine-

sible for drug efﬁcacy.

sensitive

mutation,

and

M1652R,

a

mexiletine-

resistant mutation, in addition to wild type. When
DRUG-FREE MODEL DEVELOPMENT. Mathematical

mexiletine was given to a carrier of M1652R, there

models to describe ion channel kinetics have proven

was no change in QT interval, and the patient subse-

effective

both

quently developed sudden cardiac death (ventricular

normal ion channel gating as well as mutations

ﬁbrillation). In contrast, a carrier of the R1626P

causing aberrant channel function. State-dependent

mutation exhibited a 12.5% reduction in QT interval

modeling has allowed for the description of the drug

and has remained alive with no cardiac events after

interaction with theoretical channel conformations,

7 years of follow-up at the time of publication (15).

which underlie the complex kinetics and emergent

Thus, these 2 mutants served as a natural starting

at

elucidating

mechanisms

of

behavior seen clinically (12,23,24). However, aside

point. After numerical optimization, the ﬁnal models

from the “open” state, all other states in previous

incorporated a wealth of electrophysiological data

models did not map to a speciﬁc, targetable structural

that captured current kinetics over a wide range of

correlate. The models presented here represent the

pacing protocols, as well as ﬂuorescent data that

next generation of kinetic modeling: combining

tracked

electrophysiology kinetic data with molecular-level

response to changes in membrane voltage.

the

DIII-VSD

molecular

movement

in

structural insight (10,17).
We focused on the DIII-VSD for a number of

MEXILETINE DRUG BLOCKADE. We then expanded

reasons. It is becoming increasingly clear that the 4

these models to account for mexiletine drug blockade,

VSDs can exhibit subtle dynamic changes and cause

with representations for drug access derived from the

a bidirectional effect on pore conformation. Previ-

modulated and guarded receptor hypotheses (26–28),

ous studies showed that lidocaine, a Class Ib anti-

microscopic reversibility (29), DIII-VSD results (8), and

arrhythmic drug binding to the pore, affects DIII-

clinical effects of mexiletine (15,22). Our constraint

VSD dynamics (7,25), and we previously found that

requiring equivalent afﬁnity of mexiletine to the local

LQT3 variants can alter DIII-VSD activation; DI, DII,

anesthetic

and DIV seem to play less of a role (8). Thus, we

experimentally by us (8) and others (15), ensured that

focused

our

efforts

at

incorporating

receptor

for

each mutation, veriﬁed

DIII-VSD

the observed differences in the model simulations

movement into a kinetic-based model of the Naþ

were a direct result of DIII-VSD movement. The

channel.

cellular and tissue simulations recapitulated the
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F I G U R E 7 Effects of Mex on a 100-Cell 1D Cardiac Fiber

Note that for all panels, time is on the x axis, cell number is on the y axis (1/100), and voltage is in the z axis. Full details of the ﬁber simulation are in the Supplemental
Material. The last 2 beats of a 50-beat simulation at BCL2000 are shown for each condition. (A) Schematic of a 1-dimensional (1D) cardiac ﬁber. Single ventricular
myocytes were electrotonically “coupled together” by simulated gap junctions. The ﬁber was stimulated at cell 1, and currents and transmembrane voltage were
recorded for each cell in the cardiac ﬁber. (B) In the absence of Mex (top), the R1626P mutation shows EADs that persist throughout ﬁber. Application of Mex 10 mM
(bottom) normalizes the AP. (C) For the M1652R mutation in the absence of Mex, the 49th and 50th beats represent a failure of the repolarization regime, indicating
sustained arrhythmia (top). Mex (10 mM) repolarizes the membrane, but sustained EADs are present throughout the ﬁber (bottom). (D) The WT drug-free model shows
narrow APs that easily propagate throughout the ﬁber (top). When the M1652R mutation is treated with 10 mM of “boosted” Mex (bottom), the AP normalizes
dramatically and resembles the WT phenotype. Abbreviations as in Figures 1 and 3.

effects seen clinically: therapeutic doses of mexiletine

dependence can best be seen in Supplemental

failed to normalize the marked APD prolongation and

Figure 9: both mutations clearly display pathologic

emergent EAD triggers seen in the M1652R mutation.

QT prolongation (as seen clinically [15]). Based on our

In the extended time course for the M1652R mutation

simulations, the M1652R displays marked variation in

(Supplemental Figure 4), chaotic behavior was noted,

rate-dependent APD, with severe prolongation only

with salvos of sustained membrane depolarization

at bradycardic pacing. The important overall distinc-

preceded by increasing APD, strikingly similar to the

tion, however, is that M1652R remains resistant to

2:1 atrioventricular block as well as sudden cardiac

therapeutic mexiletine (Figure 3), whereas R1626P can

death/ventricular ﬁbrillation at the whole heart level

effectively be treated with current therapies even at

seen clinically (15). Conversely, the R1626P mutation

tachycardic

exhibited a 28% reduction in APD 90 from baseline with

Supplemental Figure 9 represent mexiletine 10 m M).

mexiletine 10 m M, similar to clinical results.

pacing

(dashed

blue

traces

in

Based on our modeling, we found that R1626P

We chose to simulate slow pacing frequencies,

signiﬁcantly prolonged the QT interval even more

given that LQT3 arrhythmia syndromes are brady-

than M1652R in single-cell simulations. Furthermore,

cardia dependent, happening mostly during sleep and

Figure 3F shows that mid-dose mexiletine (5 m M) was

periods of inactivity (30). Often, they are much less

not particularly effective for the R1626P mutation,

pronounced during normal (and fast) heart rates,

which displays beat-to-beat variability in APD. How-

given the rate-dependent QT shortening. This rate

ever, we found no simulations that suggested further
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degeneration of this variability (e.g., sustained failure

preferred over amiodarone for long-term management

of repolarization for example), as was seen with

of ventricular arrhythmia, given the long-term conse-

M1652R (Supplemental Figure 4). Simulating a clinical

quences of chronic amiodarone therapy (pulmonary,

approach, we found that we could overcome this

liver, thyroid, and cornea deposition). Interestingly,

chaotic behavior by applying high-dose mexiletine

mexiletine has also been used to treat neuropathic

(10 m M) with R1626P. Whether beat-to-beat variability

pain (31). Although widely used, tolerance to mex-

versus EADs play more of a proarrhythmic role is still

iletine is inversely proportional to the dose, with

unclear clinically, although these mechanisms are

gastrointestinal distress and nausea often limiting

likely a continuum of similar phenomena (e.g., EADs

high therapeutic concentrations.

can lead to beat-to-beat variability and vice versa).
RATIONAL DESIGN OF MEXILETINE BOOSTER. We

then sought to leverage computational modeling to
rationally design a precision-targeted, molecularly
based therapy to enhance mexiletine. The data
explicitly reveal 3 positions of the DIII-VSD and suggest a fourth: 1) the rested position (R), in which DIIIVSD is in a “down” position, drug is inhibited from
receptor access, and the DIII-VSD is maximally ﬂuorescent; 2) the ﬁrst activated state (A1), in which the
DIII-VSD has moved progressively “up” in the membrane and ﬂuorescence starts to quench, but the receptor is still blocked; 3) the second activated state
(A2), in which DIII is fully “up” and ﬂuorescence is
maximally quenched, and which allows for drug
binding; and 4) DIII-VSD is fully “up” but the channel
has shifted to a kinetically inactivated regime. This
fourth regime is based on our biotin experiment
(Figure 4), as well as our previous studies (8,18),
which strongly suggest that the DIII-VSD plays a
critical role in channel inactivation.
Our approach to designing an in silico mexiletine
booster was therefore to optimize the drug-free rate
constants responsible for DIII-VSD movement in the
MR mutation to simulate the hyperpolarizing shift in
SSA of MR back to WT, and a 2-fold increase in tonic
block and UDB. Simply by changing the rates governing the drug-free DIII-VSD movement, we were
able to simulate the effects of “holding up” DIII-VSD
on drug binding. In our computational simulations
(Figure 5A), the mexiletine booster effectively “trapped” DIII-VSD in the up position throughout the action potential and revealed a crucial result: a
relatively small change in DIII-VSD ﬂuorescence at
resting membrane potential (75% vs. 90% with the
mexiletine booster) had a dramatic effect on mexiletine’s clinical efﬁcacy.

749

A New Molecular Target for Antiarrhythmic Drugs

As a necessary ﬁrst step and proof-of-concept, we
focused on 2 LQT3 mutations that represent the “extremes” of DIII-VSD sensitivity to mexiletine. By
framing the modeling study in terms of these 2 mutations, however, we were able to delineate the putative molecular mechanism that underlies Na V 1.5
sensitivity to mexiletine, regardless of the presence
or absence of a mutation. In our previous study (8),
we further found a strong correlation between DIIIVSD activation and mexiletine sensitivity (Figure 4
and Online Table II in the paper by Zhu et al. [8]). We
also found that WT channels are not particularly
sensitive to mexiletine, obviating high doses of
mexiletine used clinically with increased side effects
for modest therapeutic beneﬁt. Thus, it is conceivable
that the booster strategy could work for WT channels
implicated in varied cardiac arrhythmia syndromes
(e.g., ventricular tachycardia in which mexiletine is
commonly used) by further hyperpolarizing the WT
DIII-VSD activation voltage, which would result in
increased WT sensitivity.
Drug development remains a markedly expensive
and time-consuming endeavor fraught with potential
failure throughout the development cycle. The
computational modeling approach presented here
may be a novel strategy to increase the chances of
success by rationally designing drugs in silico while
simultaneously assessing markers of success and
failure at multiple spatial and time scales. The
strength of computational modeling is highlighted by
a few key results; namely, we were able to rationally
design a drug molecule based on key molecular
movements of the Naþ channel, and then test those
predictions in coupled higher dimensional tissue.
Second, we were able to perform an in silico safety
analysis to assess for hallmark proarrhythmic sequelae
of Class I drugs, namely conduction block. Finally, we
were able to use the model to quantify the strength of

CLINICAL UTILITY AND IMPLICATIONS. Mexiletine

our mexiletine booster through an “equivalence”

remains widely prescribed, most commonly for ma-

dose-ﬁnding simulation. Rather than de novo drug

lignant ventricular tachycardia. In contrast to ﬂecai-

design of a new antiarrhythmic drug, our model sug-

nide, it can be used in both structurally normal and

gests a potential polypharmaceutical strategy to use 2

abnormal, infarcted hearts. It is often used as an oral

drugs with synergistic effects: a commonly prescribed

lidocaine analogue in those patients who derived

antiarrhythmic drug that accesses the local anesthetic

clinical beneﬁt from intravenous lidocaine. It is

drug receptor on the Na þ channel combined with a
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DIII-VSD modulator for increased antiarrhythmic ef-

CONCLUSIONS

ﬁcacy. As shown in the state-dependent drug-binding
analysis of Supplemental Figures 3 and 4, a relatively

We have developed a model of the Na þ channel that

small increase in DIII-VSD movement can have a dra-

for the ﬁrst time includes explicit representation of

matic effect on therapeutic doses of mexiletine.

the molecular movements which shape the action

This “boosted” approach, or pharmacokinetic

potential and form the basis of the differential

enhancement, has been used previously with notable

sensitivity to the common antiarrhythmic drug

examples, including human immunodeﬁciency virus

mexiletine. After expanding the model to account for

antiretroviral agents, drugs for Parkinson’s disease,

the pharmacokinetic variables of mexiletine drug

and cancer immunotherapy. The addition of a

binding and the role of the DIII-VSD, the model was

“booster,” in this case an allosteric modulator, com-

used to develop a precision-targeted mexiletine

bined with a pore blocker adds an entirely new

booster

dimension to the existing parameter space of antiar-

mexiletine-resistant LQT3 mutation. Our results

rhythmic drug efﬁcacy. Although we tested this

suggest a promising future avenue of drug develop-

approach with LQT3 and mexiletine, we expect that a

ment, namely exploitation of nontraditional ion

similar strategy is widely applicable to those with

channel drug targets, which allows for precision-

that

was

able

to

effectively

rescue

a

malignant and refractory ventricular tachycardia both

targeted and mutation-speciﬁc pharmacotherapy for

from ischemic heart failure and nonischemic, inheri-

both LQT3 mutations and an enhanced mexiletine for

ted arrhythmia syndromes. We further expect that

ventricular tachycardia, with a more favorable side

boosting other Class I drugs could yield similar

effect proﬁle.

beneﬁt.
STUDY LIMITATIONS. Although

the Naþ channel

ADDRESS FOR CORRESPONDENCE: Dr. Jonathan R.

model is highly complex and is coupled with a

Silva,

highly parameterized human ventricular myocyte

Washington University in St. Louis, One Brookings

computational model, it represents a simpliﬁcation

Drive, Whitaker Hall, Room 290G, St. Louis, Missouri

of the true underlying pathophysiology. The mo-

63130. E-mail: jonsilva@wustl.edu.

Department

of

Biomedical

Engineering,

lecular movements include only the contribution
from the DIII-VSD, as our experimental results (8)
suggest that this domain is the most important for
determining Class I antiarrhythmic drug efﬁcacy.
Future studies may incorporate the contribution of
the DIV-VSD as a next step. As noted, all current
Class I drugs are designed to have different binding
rates and afﬁnities to the channel pore; a “booster”
allows for the modulation of the state of the channel. However, it is possible that activation of DIIIVSD may be proarrhythmic. Based on our simulations, our in silico booster molecule seems to be
extremely effective as an adjunct therapeutic strategy with mexiletine and could be a clinically useful
therapy.

However,

such

a

molecule

does

not

currently exist, and in fact, despite the existence of
DIV-VSD–binding molecules, we are aware of no
DIII-VSD molecule currently in clinical development.
We further note that we used a saturating concentration of biotin, and our simulations of “booster”
necessarily pushed the DIII-VSD into a nearly complete “upward” position to ﬁt the desired higher
afﬁnity tonic and use-dependent block. Theoretically, one could pursue further dose-ﬁnding strategies to “ﬁne-tune” the desired therapeutic effects of
the “booster” molecule. Although a booster does not
exist currently, this study provides a rationale to

PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Class I
antiarrhythmic therapies remain suboptimal given the
inability to predict efﬁcacy and potential proarrhythmic side effects. The Class Ib drug mexiletine has
been show to have differential efﬁcacy based on key
molecular determinants of the Naþ channel. This
study used computational modeling to understand
the molecular basis of drug efﬁcacy, and then
designed an in-silico mexiletine booster that could
improve efﬁcacy.
TRANSLATIONAL OUTLOOK: Drug discovery remains expensive, time-consuming, and has an unacceptably high failure rate. Computational modeling
approaches to drug discovery represent a novel tool
to design and test precision-targeted therapeutic
agents, premised on a detailed understanding of the
molecular underpinnings of drug efﬁcacy. By exploiting nontraditional ion channel drug targets, we can
add an entirely new dimension to the wide parameter
space of traditional antiarrhythmic drugs to develop
more precision-targeted and potent Class I therapeutic agents.

pursue such a molecule.
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